Swedish Orphan Biovitrum AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 5,168 million compared to SEK 3,999 million a year ago. Net income was SEK 94 million compared to SEK 451 million a year ago. Basic earnings per share from continuing operations was SEK 0.3. Diluted earnings per share from continuing operations was SEK 0.3.
For the nine months, sales was SEK 15,280 million compared to SEK 12,800 million a year ago. Net income was SEK 1,383 million compared to SEK 1,252 million a year ago. Basic earnings per share from continuing operations was SEK 4.43. Diluted earnings per share from continuing operations was SEK 4.39.